These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29897499)

  • 1. Treatment of type 2 diabetes: future approaches.
    Bailey CJ; Day C
    Br Med Bull; 2018 Jun; 126(1):123-137. PubMed ID: 29897499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of glucose-lowering drugs to reduce cardiovascular events.
    Zarich SW
    Curr Diab Rep; 2009 Feb; 9(1):87-94. PubMed ID: 19192430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.
    Scheen AJ; Charbonnel B
    Diabetes Metab; 2014 Jun; 40(3):176-85. PubMed ID: 24792220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypoglycemic treatment of type 2 diabetes].
    Thorsby P; Kilhovd B; Sletmo R; Martinsen S; Birkeland KI
    Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2434-40. PubMed ID: 11475233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive glucose control on microvascular events in people with type 2 diabetes.
    Drug Ther Bull; 2017 Jun; 55(6):62. PubMed ID: 28566321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating diabetes today with gliclazide MR: a matter of numbers.
    Avogaro A
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():14-9. PubMed ID: 22118706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
    Eriksson L; Nyström T
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
    Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
    Alonso Fernández M
    Semergen; 2018 Jun; 44 Suppl 1():26-32. PubMed ID: 30322470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of salicylates in type 2 diabetes.
    Rumore MM; Kim KS
    Ann Pharmacother; 2010; 44(7-8):1207-21. PubMed ID: 20516365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.